We joined Petros Grivas (University of Washington School of Medicine) at ESMO 2019 to discuss immune checkpoint inhibitors and novel agents in the treatment of metastatic urothelial cancer.
Questions
1. How have immune checkpoint inhibitors changed the treatment landscape for metastatic urothelial cancer? (0:04)
2. What progress has been made in identifying biomarkers of response to immune checkpoint inhibitors in urothelial cancer? (1:35)
3. What is the potential for combined treatment approaches using programmed cell death 1 (PD-1) and CTLA-4 inhibitors in urothelial cancer? (2:48)
4. How can we best manage toxicity from immune checkpoint inhibitors? (4:32)
5. Which novel agents are in clinical development for metastatic urothelial cancer? (6:37)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosure: Petros Grivas has acted as a consultant for AstraZeneca, Bayer, Biocept, Bristol-Myers Squibb, Clovis Oncology, Dendreon, Driver, EMD Serono, Exelixis, Foundation Medicine, Genentech, Genzyme, Heron Therapeutics, Janssen, Merck & Co., Mirati Therapeutics, Pfizer, Seattle Genetics and QED Therapeutics. He has been involved in educational programs with Bristol-Myers Squibb, Genentech Research Funding to Institution, AstraZeneca, Bayer, Genentech/Roche, Merck & Co., Mirati Therapeutics, Oncogenex, Pfizer, Clovis Oncology, Bavarian Nordic, Immunomedics, Debiopharm and Bristol-Myers Squibb.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
